Tiny silica nanoparticles engineered to seek out prostate cancer caused tumor cells to self-destruct and supercharged the ...

Prostate cancer is one of the most common cancers diagnosed in men. Although it is the second-leading cause of cancer-related deaths for men in the U.S., it is also highly treatable, especially when ...

Prostate cancer is a disease in which cancer cells form in the tissues of the prostate, a gland in the male reproductive system. The National Cancer Institute states that about 1 in 8 males will be ...

According to the institute, a single, reliable test to differentiate aggressive, life-threatening cancers from slower-growing ...

The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...

The treatment, called Pasritamig, teaches the immune system's T cells to target and attack cancer cells in the prostate.

Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over ...

The UCSF Helen Diller Family Comprehensive Cancer Center announced today that the UCSF Prostate Cancer Program is the recipient of the National Cancer Institute’s (NCI) Specialized Programs of ...

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...

FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...

The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new ...